Drugmakers fall as Trump signals announcement on medicine costs

ReutersMay 6, 2025 3:21 PM

View all comments（0）



Shares of U.S drugmakers fall after President Trump signaled he would make an announcement next week on the cost of medicines

Shares of Eli Lilly LLY.N and Abbvie ABBV.N fall 3% each, Merck MRK.N down 2.5%, Gilead GILD.O slip 2.4%, Amgen AMGN.O down 2.2%, Pfizer PFE.N fall 1.7%

The S&P 500 healthcare sector .SPXHC falls 1.5%

Trump said to reporters gathered at the White House the U.S. was being ripped off on medicine costs when compared to the rest of the world

He also said that he plans to announce pharmaceutical tariffs over the next two weeks

Trump's recent comments imply that pharma-specific tariff proposals are coming, but may not be as bad as expected, Jefferies says

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Nvidia Surges Over 3% in Overnight Trading, Reports Say US Approved Sale of NVDA H200 Chips to 10 Chinese Companies

TradingKey - During the US overnight trading session on May 14 ET, Nvidia (NVDA.US) shares surged, with gains briefly exceeding 3% and hitting a session high of $232.35.

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

Featured Tools